Twenty-five million Americans suffer from ulcers. An ulcer is a sore or hole in the lining of the stomach or duodenum (the first part of the small intestine). People of any age can get an ulcer and women are affected just as often as men.
Helicobacter pylori (H. pylori) is a bacterium that lives on the lining of the stomach. Although we used to think that spicy food, acid, and stress were the major causes of ulcers, we now know that nine out of ten ulcers are caused by H. pylori. Medicines that reduce stomach acid may make you feel better, but your ulcer may come back. Here's the good news: Since most ulcers are caused by this bacterial infection, they can be cured with the right antibiotics.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that researchers who invented DSC127 have been awarded a $4.5 million, 16-month grant by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority to investigate preclinically the use of DSC127 in the treatment of skin injuries associated with acute radiation exposure.
The Association for the Advancement of Wound Care has developed three educational brochures for the care of skin and treatment of wounds. Widely used by clinicians as a resource for patients and their caregivers, AAWC recently converted the brochures into Spanish due to popular demand.
"A rise in global funding for research into neglected diseases needs to be matched by a continued focus on delivering practical new ways to curb sickness in the developing world," according to the third annual report by the Global Funding of Innovation for Neglected Diseases released on Wednesday, Reuters reports.
Apricus Biosciences, Inc., announced today that it is currently in discussions with the U.S. Food and Drug Administration ("FDA") relating to the PrevOnco™ Special Protocol Assessment ("SPA") Phase III protocol submitted by the Company in December 2010.
Sanofi-aventis and Sunnybrook Health Sciences Centre announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack of sensation and neuropathic ulcers that are complicated by peripheral arterial disease, commonly called neuroischemic diabetic foot ulcers.
Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.
SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, announces that it has raised gross proceeds of $4,102,660 from the exercise of Options that were issued as part of the sale of Units to accredited investors during 2010. The Options had an expiration date of January 31, 2011.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced positive results from its Phase 2 clinical trial with DSC127 in patients with diabetic foot ulcers, including meeting the trial's primary endpoint, the proportion of study ulcers healed by 12 weeks as defined by 100% epithelialized with no drainage, as well as all secondary endpoints measured at this time.
A new study led by researchers at Rhode Island Hospital in collaboration with the University of Rhode Island and EpiVax. Inc, a privately owned vaccine development company in Providence, RI, has identified a potential vaccine capable of reducing colonization of Helicobacter pylori -- a known cause of gastritis, ulcer disease and cancer.
Kinetic Concepts, announced today an agreement to license Wright Medical Group, GRAFTJACKET brand for use in marketing the LifeCell™ acellular human dermal-based regenerative tissue matrix for wound applications such as diabetic foot ulcers and venous stasis ulcers.
Cumberland Pharmaceuticals Inc. today announced the publication of data affirming the safety and efficacy of Caldolor® (ibuprofen) Injection in treating post-operative pain in hospitalized patients. A Phase III study published in the peer-reviewed journal Pain Practice concluded that IV ibuprofen significantly reduced both morphine use and self-reported pain intensity in patients recovering from abdominal hysterectomy compared to morphine alone.
The most common connective tissue cell in animals is the fibroblast, which plays an important role in healing wounds. But Dr. Neta Erez of Tel Aviv University's Sackler Faculty of Medicine has now demonstrated that fibroblasts can also do a body great harm, helping to "recruit" immune cells for tumor growth.
China Shenghuo Pharmaceutical Holdings, a China-based pharmaceutical company engaged in the research, development, manufacture, and marketing of Traditional Chinese Medicine, nutritional supplement and cosmetic products, today announced that "Lixuwang", the trademark of its best selling product, Xuesaitong Capsule, was awarded the Chinese Well-Known Trademark Honor by the State Administration for Industry and Commerce of China.
Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the U.S. Food and Drug Administration (FDA) authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia (CLI).
During ICMS Annual International Congress on Regenerative and Cell Based Medicine Conference held on November 12, 2010 in Las Vegas, Nevada, it was announced that a patient with complications of diabetes gangrene recovered from foot ulcer through stem cell therapy.
Oxygen Biotherapeutics, Inc. and privately held Sarasota Medical Products, Inc. (SMP) of Sarasota, FL, today announced they signed a Binding Letter of Intent to determine the feasibility of pursuing a joint research and development venture for treating chronic ischemic wounds. The venture will be based on combining Oxygen's Wundecyte™ PFC formulation with SMP's topical medical devices.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Digestive Disease Specialists, Inc. has selected its ProVation MD software for gastroenterology procedure documentation and coding.
Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of infectious diseases, announced it has successfully filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) to test SQ109 in patients suffering from H. pylori-related duodenal ulcers, and can now begin Phase 2 studies.
Loyola University Health System revenue specialist Judy Williams, RN, CEN, TNS, recently took on a nontraditional nursing role, which resulted in a significant cost savings for the organization. Williams oversees fiscal responsibility for the Emergency Department. In this position, she has identified opportunities to overcome billing obstacles through intradepartmental collaboration and nurse education on proper documentation for reimbursement.
Apricus Biosciences, Inc., today announced that it has filed the protocol for a proposed Phase 3 clinical trial of PrevOnco, its proprietary treatment for hepatocellular carcinoma (liver cancer), with the U.S. Food and Drug Administration (FDA).
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.